Manulife (Manufacturers Life Insurance)
ESPR

Manulife (Manufacturers Life Insurance)’s Esperion Therapeutics ESPR Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$177K Sell
64,523
-5,517
-8% -$17.5K ﹤0.01% 2494
2025
Q4 		$259K Buy
70,040
+235
+0.3% +$759 ﹤0.01% 2411
2025
Q3 		$185K Sell
69,805
-2,900
-4% -$5.61K ﹤0.01% 2606
2025
Q2 		$71.6K Buy
72,705
+4,979
+7% +$4.99K ﹤0.01% 2832
2025
Q1 		$97.5K Buy
67,726
+503
+0.7% +$927 ﹤0.01% 2697
2024
Q4 		$148K Sell
67,223
-2,473
-4% -$5.77K ﹤0.01% 2723
2024
Q3 		$115K Sell
69,696
-1,792
-3% -$3.62K ﹤0.01% 2830
2024
Q2 		$159K Buy
+71,488
New +$168K ﹤0.01% 2689
2023
Q2 		– Sell
-27,940
Closed -$44.4K – 2992
2023
Q1 		$44.4K Hold
27,940
– – ﹤0.01% 2878
2022
Q4 		$174K Buy
27,940
+1,631
+6% +$11.7K ﹤0.01% 2628
2022
Q3 		$176K Sell
26,309
-255
-1% -$1.75K ﹤0.01% 2639
2022
Q2 		$169K Buy
26,564
+1,026
+4% +$5.82K ﹤0.01% 2732
2022
Q1 		$118K Buy
25,538
+13,621
+114% +$58.4K ﹤0.01% 2932
2021
Q4 		$60 Sell
11,917
-3,181
-21% -$25.5K ﹤0.01% 3084
2021
Q3 		$182K Sell
15,098
-394
-3% -$5.74K ﹤0.01% 3015
2021
Q2 		$328K Buy
15,492
+447
+3% +$10.8K ﹤0.01% 2754
2021
Q1 		$422K Sell
15,045
-849
-5% -$25K ﹤0.01% 2400
2020
Q4 		$413K Buy
15,894
+694
+5% +$20.8K ﹤0.01% 2319
2020
Q3 		$565K Sell
15,200
-274
-2% -$10.9K ﹤0.01% 1945
2020
Q2 		$737K Sell
15,474
-687
-4% -$28.7K ﹤0.01% 1764
2020
Q1 		$510K Buy
16,161
+1,079
+7% +$56.9K ﹤0.01% 1829
2019
Q4 		$899K Sell
15,082
-533
-3% -$24K ﹤0.01% 1731
2019
Q3 		$590K Sell
15,615
-26
-0.2% -$1.03K ﹤0.01% 1930
2019
Q2 		$728K Buy
15,641
+427
+3% +$20.1K ﹤0.01% 1827
2019
Q1 		$611K Buy
15,214
+1,133
+8% +$50.8K ﹤0.01% 1970
2018
Q4 		$648K Sell
14,081
-1,215
-8% -$58.5K ﹤0.01% 1822
2018
Q3 		$679K Sell
15,296
-2,107
-12% -$96.7K ﹤0.01% 2065
2018
Q2 		$682K Buy
17,403
+4,287
+33% +$217K ﹤0.01% 2143
2018
Q1 		$949K Sell
13,116
-39
-0.3% -$2.86K ﹤0.01% 1871
2017
Q4 		$867K Buy
13,155
+60
+0.5% +$3.23K ﹤0.01% 1940
2017
Q3 		$655K Buy
13,095
+1,248
+11% +$60.2K ﹤0.01% 2086
2017
Q2 		$549K Sell
11,847
-361
-3% -$13.3K ﹤0.01% 2217
2017
Q1 		$432K Buy
12,208
+982
+9% +$22.5K ﹤0.01% 2301
2016
Q4 		$141K Sell
11,226
-152
-1% -$1.81K ﹤0.01% 3040
2016
Q3 		$157K Buy
11,378
+408
+4% +$4.62K ﹤0.01% 2953
2016
Q2 		$109K Buy
10,970
+1,856
+20% +$30.8K ﹤0.01% 3179
2016
Q1 		$150K Buy
9,114
+368
+4% +$5.92K ﹤0.01% 2803
2015
Q4 		$194 Hold
8,746
– – ﹤0.01% 2689
2015
Q3 		$206 Sell
8,746
-31,193
-78% -$1.96M ﹤0.01% 2629
2015
Q2 		$3.27K Buy
39,939
+35,720
+847% +$3.5M ﹤0.01% 1256
2015
Q1 		$391 Buy
4,219
+43
+1% +$2.77K ﹤0.01% 2233
2014
Q4 		$169 Buy
4,176
+3,010
+258% +$92.1K ﹤0.01% 2763
2014
Q3 		$29 Buy
+1,166
New +$18.5K ﹤0.01% 3378

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s ESPR Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) reduced its Esperion Therapeutics (ESPR) stake by 7.9% in Q1 2026, selling an estimated $17.5K and leaving 64,523 shares worth $177K. The position accounts for ﹤0.01% of the portfolio, ranked #2494.

Manulife (Manufacturers Life Insurance) first reported a position in ESPR in Q3 2014 and has held it in 43 quarters since. The position peaked at $949K in Q1 2018. 206 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

  • Manulife (Manufacturers Life Insurance) held 64,523 shares of Esperion Therapeutics worth $177K as of Q1 2026.
  • Manulife (Manufacturers Life Insurance) sold 5,517 Esperion Therapeutics shares in Q1 2026, an estimated $17.5K.
  • Esperion Therapeutics made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #2494 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in Esperion Therapeutics in Q3 2014 and has held it in 43 quarters since.
  • Manulife (Manufacturers Life Insurance)'s Esperion Therapeutics position peaked at $949K in Q1 2018.
  • 206 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.